Imaging markers of intracerebral hemorrhage expansion in patients with unclear symptom onset

Background: Hematoma expansion (HE) is common and associated with poor outcome in intracerebral hemorrhage (ICH) with unclear symptom onset (USO). Aims: We tested the association between non-contrast computed tomography (NCCT) markers and HE in this population. Methods: Retrospective analysis of patients with primary spontaneous ICH admitted at five centers in the United States and Italy. Baseline NCCT was analyzed for presence of the following markers: intrahematoma hypodensities, heterogeneous density, blend sign, and irregular shape. Variables associated with HE (hematoma growth > 6 mL and/or > 33% from baseline to follow-up imaging) were explored with multivariable logistic regression. Results: Of 2074 patients screened, we included 646 subjects (median age = 75, 53.9% males), of whom 178 (27.6%) had HE. Hypodensities (odds ratio (OR) = 2.67, 95% confidence interval (CI) = 1.79–3.98), heterogeneous density (OR = 2.16, 95% CI = 1.46–3.21), blend sign (OR = 2.28, 95% CI = 1.38–3.75) and irregular shape (OR = 1.82, 95% CI = 1.21–2.75) were independently associated with a higher risk of HE, after adjustment for confounders (ICH volume, anticoagulation, and time from last seen well (LSW) to NCCT). Hypodensities had the highest sensitivity for HE (0.69), whereas blend sign was the most specific marker (0.90). All NCCT markers were more frequent in early presenters (time from LSW to NCCT ⩽ 6 h, n = 189, 29.3%), and more sensitive in this population as well (hypodensities had 0.77 sensitivity). Conclusion: NCCT markers are associated with HE in ICH with USO. These findings require prospective replication and suggest that NCCT features may help the stratification of HE in future studies on USO patients.

[1]  S. Greenberg,et al.  Hematoma Expansion in Intracerebral Hemorrhage With Unclear Onset , 2021, Neurology.

[2]  M. Elkind,et al.  Hematoma expansion is more frequent in deep than lobar intracerebral hemorrhage , 2020, Neurology.

[3]  A. Charidimou,et al.  Noncontrast CT markers of intracerebral hemorrhage expansion and poor outcome , 2020, Neurology.

[4]  J. Goldstein,et al.  Ultra‐Early Blood Pressure Reduction Attenuates Hematoma Growth and Improves Outcome in Intracerebral Hemorrhage , 2020, Annals of neurology.

[5]  Jun Zhang,et al.  Letter: Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data[deg]. , 2020, Turkish neurosurgery.

[6]  A. Demchuk,et al.  Redefining Hematoma Expansion With the Inclusion of Intraventricular Hemorrhage Growth , 2020, Stroke.

[7]  L. Cala,et al.  Noncontrast Computed Tomography Signs as Predictors of Hematoma Expansion, Clinical Outcome, and Response to Tranexamic Acid in Acute Intracerebral Hemorrhage , 2019, Stroke.

[8]  Craig S. Anderson,et al.  Standards for Detecting, Interpreting, and Reporting Noncontrast Computed Tomographic Markers of Intracerebral Hemorrhage Expansion , 2019, Annals of neurology.

[9]  C. Cordonnier,et al.  Is Hyperselection of Patients the Right Strategy? , 2019, JAMA neurology.

[10]  A. Demchuk,et al.  Effect of Recombinant Activated Coagulation Factor VII on Hemorrhage Expansion Among Patients With Spot Sign-Positive Acute Intracerebral Hemorrhage: The SPOTLIGHT and STOP-IT Randomized Clinical Trials. , 2019, JAMA neurology.

[11]  A. Demchuk,et al.  Interrater and Intrarater Measurement Reliability of Noncontrast Computed Tomography Predictors of Intracerebral Hemorrhage Expansion , 2019, Stroke.

[12]  E. Heuvel,et al.  Testing homogeneity of effect sizes in pooling 2x2 contingency tables from multiple studies: a comparison of methods , 2018 .

[13]  Javier M Romero,et al.  Blood pressure reduction and noncontrast CT markers of intracerebral hemorrhage expansion , 2017, Neurology.

[14]  S. Greenberg,et al.  Intensive Blood Pressure Reduction and Spot Sign in Intracerebral Hemorrhage: A Secondary Analysis of a Randomized Clinical Trial , 2017, JAMA neurology.

[15]  J. Teitelbaum,et al.  Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage , 2016, Neurocritical Care.

[16]  Mario Zuccarello,et al.  Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2015, Stroke.

[17]  G. Fink,et al.  Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. , 2015, JAMA.

[18]  S. Greenberg,et al.  Predicting hematoma expansion after primary intracerebral hemorrhage. , 2014, JAMA neurology.

[19]  R. Salman,et al.  Eligibility for randomized trials of treatments specifically for intracerebral hemorrhage: community-based study , 2013, Trials.

[20]  S. Greenberg,et al.  CTA Spot Sign Predicts Hematoma Expansion in Patients with Delayed Presentation After Intracerebral Hemorrhage , 2012, Neurocritical Care.

[21]  Eric E. Smith,et al.  Defining hematoma expansion in intracerebral hemorrhage , 2011, Neurology.

[22]  Y. Fujii,et al.  Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data , 2018 .